Ambrx Biopharma (AMAM) Stock Forecast & Price Target

Notice: This company has been marked as potentially delisted and may not be actively trading.

Stock Analysis Analyst Forecasts Headlines Insider Trades Ownership Trends

Ambrx Biopharma - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold
Based on 7 Analyst Ratings

Based on 7 Wall Street analysts who have issued ratings for Ambrx Biopharma in the last 12 months, the stock has a consensus rating of "Hold." Out of the 7 analysts, 4 have given a hold rating, and 3 have given a buy rating for AMAM.

Consensus Price Target

$23.29
-16.84% Downside

High Forecast	$32.00
Average Forecast	$23.29
Low Forecast	$9.00

According to the 7 analysts' twelve-month price targets for Ambrx Biopharma, the average price target is $23.29. The highest price target for AMAM is $32.00, while the lowest price target for AMAM is $9.00. The average price target represents a forecasted downside of -16.84% from the current price of $28.00.

Type	Current Forecast 9/8/23 to 9/7/24	1 Month Ago 8/9/23 to 8/8/24	3 Months Ago 6/10/23 to 6/9/24	1 Year Ago 9/8/22 to 9/8/23
Consensus Rating	Hold	Hold	Hold	Moderate Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	3 Buy rating(s)	3 Buy rating(s)	3 Buy rating(s)	5 Buy rating(s)
Hold	4 Hold rating(s)	4 Hold rating(s)	4 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$23.29	$23.29	$23.29	$21.33
Forecasted Upside	-16.84% Downside	49.25% Upside	49.25% Upside	79.67% Upside

Get Ambrx Biopharma Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for AMAM and its competitors with MarketBeat's FREE daily newsletter.

Ad Behind the Markets

⭕ [URGENT] Buy Alert just triggered

My absolute favorite stock just hit a critical "buy now" trigger price.

Click here for the ticker >>>

AMAM Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

AMAM Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Ambrx Biopharma Stock vs. The Competition

Type	Ambrx Biopharma	Medical Companies	S&P 500
Consensus Rating Score	2.43	2.77	2.51
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	-16.84% Downside	1,207.55% Upside	11.36% Upside
News Sentiment Rating	Neutral News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
1/16/2024	Robert W. Baird 2 of 5 stars		Reiterated Rating	Outperform ➝ Neutral	$28.00	+1.27%
1/12/2024	Cantor Fitzgerald 3 of 5 stars	L. Chen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight
1/10/2024	JMP Securities 2 of 5 stars		Reiterated Rating	Market Outperform ➝ Market Perform
1/9/2024	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Y. Zhi Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$26.00 ➝ $28.00	+2.53%
11/15/2023	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$10.00 ➝ $9.00	-7.12%
11/14/2023	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$33.00 ➝ $32.00	+269.51%
Get the Latest News and Ratings for AMAM and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Ambrx Biopharma and its competitors with MarketBeat's FREE daily newsletter.
9/12/2023	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$26.00	+123.37%
6/1/2023	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$30.00	+106.47%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 08:16 PM ET.

AMAM Forecast - Frequently Asked Questions

What is Ambrx Biopharma's forecast for 2024?: According to the research reports of 7 Wall Street equities research analysts, the average twelve-month stock price forecast for Ambrx Biopharma is $23.29, with a high forecast of $32.00 and a low forecast of $9.00.
Should I buy or sell Ambrx Biopharma stock right now?: 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ambrx Biopharma in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" AMAM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMAM, but not buy additional shares or sell existing shares.
Does Ambrx Biopharma's stock price have much upside?: According to analysts, Ambrx Biopharma's stock has a predicted upside of 49.25% based on their 12-month stock forecasts.
Do Wall Street analysts like Ambrx Biopharma more than its competitors?: Analysts like Ambrx Biopharma less than other "medical" companies. The consensus rating for Ambrx Biopharma is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how AMAM compares to other companies.